Molina-Infante Javier, Lucendo Alfredo J
Department of Gastroenterology, Hospital San Pedro de Alcantara, C/ Pablo Naranjo s/n 10003, Caceres, Spain.
Expert Rev Gastroenterol Hepatol. 2014 Nov;8(8):925-34. doi: 10.1586/17474124.2014.919851. Epub 2014 May 16.
Eosinophilic esophagitis (EoE) has emerged as a common cause of dysphagia and food impaction in children and adults. A trial of proton pump inhibitor (PPI) therapy is a mandatory diagnostic first step, given that at least one third of patients with suspected EoE will have PPI-responsive esophageal eosinophilia. Once EoE is diagnosed, short-and long-term therapeutic decision making may rely on patient symptoms, phenotype (inflammatory vs fibrostenotic) and preferences. Currently, the most reliable therapeutic targets are mucosal healing and caliber abnormalities resolution. Topical steroids followed by endoscopic dilation are recommended in symptomatic narrow caliber esophagus/strictures, whereas either topical steroids or dietary therapy are good short-term options for mucosal inflammation. Maintenance anti-inflammatory therapy is necessary to prevent esophageal fibrotic remodeling and stricture formation.
嗜酸性食管炎(EoE)已成为儿童和成人吞咽困难及食物嵌塞的常见原因。鉴于至少三分之一疑似EoE的患者会出现质子泵抑制剂(PPI)反应性食管嗜酸性粒细胞增多,因此进行PPI治疗试验是强制性的首要诊断步骤。一旦确诊EoE,短期和长期的治疗决策可能取决于患者的症状、表型(炎症性与纤维狭窄性)和偏好。目前,最可靠的治疗目标是黏膜愈合和管径异常的解决。对于有症状的狭窄管径食管/狭窄,建议先使用局部类固醇,然后进行内镜扩张,而局部类固醇或饮食疗法是黏膜炎症的良好短期选择。维持抗炎治疗对于预防食管纤维化重塑和狭窄形成是必要的。